Generated by AI
Summary of Sep 17's posts. Generated by AI.
Summary of Sep 15's posts. Generated by AI.
Summary of Jun 27's posts. Generated by AI.
Summary of Sep 15's posts. Generated by AI.
Investors talking about BNGO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Bionano Genomics Inc. is a life sciences instrumentation company focused on genome analysis. The company develops and commercializes optical genome mapping solutions, including the Saphyr and Stratys systems, along with consumables, sample-preparation kits, and software used to analyze structural variation and other genomic changes. Its platform is designed for researchers and clinicians working in basic, translational, and clinical research, supporting applications in cytogenetics, rare disease studies, reproductive health, prenatal genetics, and oncology research. Bionano Genomics also offers data analysis tools that help laboratories visualize, interpret, and report genomic findings across multiple platforms. Headquartered in San Diego, California and founded in 2003, Bionano Genomics serves customers in global research and clinical markets with an integrated workflow for genome mapping and interpretation.
Website9540 Towne Centre Drive
San Diego, CA, 92121
United States
The latest articles about BNGO.
Bionano Genomics Inc (BNGO) posted 12% revenue growth to $8.3 million with record consumables and flow cell volumes, but software revenue fell 31% and supply constraints limited upside.
Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.